CD4 + T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy.
Minglu XiaoLuoyingzi XieGuoshuai CaoShun LeiPengcheng WangZhengping WeiYuan LuoJingyi FangXingxing YangQizhao HuangLifan XuJunyi GuoShuqiong WenZhiming WangQing WuJianfang TangLisha WangXiangyu ChenCheng ChenYanyan ZhangWei YaoJianqiang YeRan HeJun HuangLilin YePublished in: Journal for immunotherapy of cancer (2022)
1 and CTL response, leading to the efficient tumor control. This strategy can also potentiate PD-1/PD-L1 immune checkpoint blockade (ICB) against cancer.